ArticleCureus2025
Impact of Hypertension on the Outcomes of Patients With High-Grade Gliomas: A Propensity-Matched Study From a Global Federated Health Research Network.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHypertension (HTN) is known to cause endothelial dysfunction, disrupting the blood-brain barrier and cerebral blood flow. Gliomas also disrupt cerebral vasculature via tumor-associated vascular abnormalities and healthy tissue displacement. This retrospective analysis aimed to study the differences between patients diagnosed with one of the three high-grade gliomas and HTN. Methods: We used TriNetX's US Collaborative Network to study the impact of HTN on adult patients with one of the three high-grade gliomas, namely, glioblastoma multiforme (GBM), astrocytoma, or oligodendroglioma (ODG), using ICD-10 (International Classification of Diseases) codes. We tracked these patients for five years to assess outcomes, including all-cause mortality, cerebral infarction, seizures, cerebral edema, and emergency endotracheal intubation.
resultsThe GBM+HTN cohort showed significantly higher risk of all-cause mortality (HR 1.18; 95% CI 1.094-1.271; p<0.000), cerebral edema (HR 1.359; 95% CI 1.236-1.494; p<0.001), seizures (HR 1.624; 95% CI 1.459-1.808; p=0.007), and hemorrhagic stroke (HR 1.255; 95% CI 1.038-1.516; p=0.015). The ODG+HTN cohort demonstrated significantly increased risk of all-cause mortality (HR 1.398; 95% CI 1.040-1.879; p=0.001), emergency endotracheal intubation (HR 1.381; 95% CI 0.590-3.230; p=0.012), and cerebral edema (HR 0.904; 95% CI 0.680-1.203; p=0.023). There were no significant differences between the HTN and control cohorts in the astrocytoma group. Conclusions: Patients with high-grade gliomas and HTN differ significantly. Patients with HTN appear to be at a higher risk of all-cause mortality, cerebral edema, seizures, and emergency endotracheal intubation, depending on tumor type. Further research is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.